About Ascentage Pharma
Ascentage Pharma is a Healthcare company based in Hong Kong (China) founded in 2009. Small molecule drugs for cancer treatment are developed. Ascentage Pharma has raised $237.5 million across 3 funding rounds from investors including ArrowMark Partners, CTS Capital Advisors and Oriza Ventures. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Ascentage Pharma was founded in 2009 in Hong Kong, China, where small molecule drugs targeting cancers are developed. The pipeline includes AT101 as a pan-Bcl-2 inhibitor for non-small cell lung cancer, HQP8361 as a c-Met inhibitor for solid tumors, APG-1387 as an IAP inhibitor for solid tumors, and HQP1351 as a Bcr-Abl kinase inhibitor for chronic myeloid leukemia. Key oncogenic drivers in human cancers are addressed by several preclinical programs.
- Headquarters Hong Kong, China
- SectorsHealthcare
- Email••••••••
- Website ascentagepharma.com
- Social LinkedIn
- Total Equity Funding$237.5M (USD)
in 3 rounds
- Latest Funding Round$150M (USD), Series C
Jul 2018
- InvestorsArrowMark Partners
& 10 more
Funding Insights of Ascentage Pharma
Ascentage Pharma has successfully raised a total of $237.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $150 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $237.5M
- Total Rounds 3
- Last Round Series C — $150M
- First Round $15.5M
(Aug 2015)
- Investors Count 11
All 3 funding rounds of Ascentage Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2018 | $150M | Series C | – | Oriza Ventures, Yuan Ming Capital | |
| Dec 2016 | $72M | Series B | – | SDIC Innovation | |
| Aug 2015 | $15.5M | Series A | – | Oriza Ventures, Yuan Ming Capital |
11 investors in total: 11 institutional.
Investors in Ascentage Pharma
Ascentage Pharma has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ArrowMark Partners, CTS Capital Advisors and Oriza Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| orizaventures.com | ||||
PE firm focused on medicine based companies | yuanmingcap.cn | Haidian, China | ||
Private equity firm investing in multiple sectors | sdicfund.com | Xicheng, China | ||
Shiyu Capital is engaged in equity investment and asset allocation. | shiyucapital.com | Beijing, China | ||
AI solutions are provided for industrial monitoring and efficiency. | founderhf.com | |||
Efung Capital is focused on global biopharmaceutical investments. | 2012 | efungcapital.com | Shenzhen, China | |
Seed and early stage tech and life sciences focused VC firm investing in companies in China | grainsvalley.com | Beijing, China | ||
BioVenture is focused on early and growth-stage healthcare investments. | 2013 | bioventure.com.cn | Suzhou, China | |
Diversified asset management services are provided to investors. | 2007 | arrowmarkpartners.com | Denver, United States | |
Financial advisory firm | 2003 | ctsca.com | Bethesda, United States |
Investor details for Ascentage Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ascentage Pharma
56 people are tracked at Ascentage Pharma (31 in leadership, 13 in board & advisors, 12 in team).
| Name | Role | Group |
|---|---|---|
Lily Wang | Head Of Ip, Senior Director, Legal Affairs & IP | Leadership |
Zhu Gang | Chief Commercial Officer | Leadership |
Lu Zhang | Director Business Development | Leadership |
Dajun Yang | Co-Founder, Chairman & CEO | Leadership |
Yifei Zhu | Chief Commercial Officer | Leadership |
Xu Yang | Director Clinical Pharmacology | Leadership |
Angel Chan | Associate Director Clinical Operation | Leadership |
Gordon Tang | VP, Discovery Chemistry | Leadership |
Ryman Men | Associate Vice President Of Data Management & Statistics | Leadership |
Paudyal Bishnuhari | Associate Medical Director, Clinical Development Department | Leadership |
Yifan Zhai | Chief Medical Officer | Leadership |
Sherry Sun | Senior Medical Director | Leadership |
Zhiyan Liang | VP, Clinical Biomarker & Translational Medicine | Leadership |
John Tang | VP & Global Head of Program Management | Leadership |
Zhihong Yang | Sr. Director, Statistics | Leadership |
Elaine Zhi | Director Of Finance | Leadership |
Freesia Chen | Sr Supply Chain Director （commercial&clinical） | Leadership |
Matthew Carney | Senior Director, Head Of Global Data Management | Leadership |
Ashutosh Pathak | Senior Vice President | Leadership |
Leo Yan | Senior Director Of Legal Affairs | Leadership |
36 more people are available in the full profile.
Complete people profiles for Ascentage Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ascentage Pharma
3 dated milestones of Ascentage Pharma across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Ascentage Pharma is founded.
- Funding First funding round of $15.5M.
- Funding Latest funding round, Series C, of $150.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ascentage Pharma
Complete news archive for Ascentage Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ascentage Pharma
Ascentage Pharma was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Ascentage Pharma is headquartered in Hong Kong, China.
Ascentage Pharma is a funded company, having raised a total of $237.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $15.5M, raised on Aug 2015.
Ascentage Pharma was founded in 2009 in Hong Kong, China, where small molecule drugs targeting cancers are developed. The pipeline includes AT101 as a pan-Bcl-2 inhibitor for non-small cell lung cancer, HQP8361 as a c-Met inhibitor for solid tumors, APG-1387 as an IAP inhibitor for solid tumors, and HQP1351 as a Bcr-Abl kinase inhibitor for chronic myeloid leukemia. Key oncogenic drivers in human cancers are addressed by several preclinical programs.
Ascentage Pharma has 11 investors. Key investors include ArrowMark Partners, CTS Capital Advisors, Oriza Ventures, CCB International, and Yuan Ming Capital.